[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351415-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351415-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","hscore-as-a-diagnostic-tool-in-erbb2-equivocal-immunohistochemistry-2-breast-cancer","HScore as a diagnostic tool in ERBB2 equivocal (immunohistochemistry 2+) breast cancer","","Retrospective laboratory study evaluates whether the HScore can classify ERBB2 immunohistochemistry (IHC) equivocal cases (2+) as positive or negative without fluorescence in situ hybridization (FISH) confirmation. Image acquisition and processing were applied to archived breast cancer tissue slides from 2014–2023, and HScore values were calculated from image-analysis software variables. Mean HScore was higher in ERBB2-positive (3.06) than ERBB2-negative cases (2.62), with ROC AUC 0.668 and limited specificity at the optimal cutoff.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/hscore-as-a-diagnostic-tool-in-erbb2-equivocal-immunohistochemistry-2-breast-cancer/351415/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/hscore-as-a-diagnostic-tool-in-erbb2-equivocal-immunohistochemistry-2-breast-cancer/351415.png","ImageObject",300,407,{"name":42,"@type":43},"Riley West","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of using HScore in ERBB2 IHC-equivocal breast cancer?","Question",{"text":63,"@type":64},"To determine whether HScore can predict ERBB2 IHC-equivocal (2+) cases as positive or negative, potentially avoiding FISH confirmation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were HScore values generated in the study?",{"text":68,"@type":64},"Image acquisition and processing were performed on previously collected tissue slides, and HScore values were calculated using variables from image analysis software.",{"name":70,"@type":61,"acceptedAnswer":71},"What diagnostic performance did HScore show compared with FISH as the gold standard?",{"text":72,"@type":64},"HScore demonstrated moderate predictive accuracy (ROC AUC 0.668) but lacked reliability to replace FISH, which remains the reference method for ERBB2 status confirmation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351415,1790193609,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099523885074,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Laboratory Medicine, 2026, 57(3), lmag006 [https://doi.org/10.1093/labmed/lmag006](https://doi.org/10.1093/labmed/lmag006)[ ](https://doi.org/10.1093/labmed/lmag006)Science  \nHScore as a diagnostic tool in ERBB2 equivocal (immunohistochemistry 2+) breast cancer  \nTasnem Alsebai, MD1; Muhammed Yaman Swied, MD1; Ricardo Cossyleon, MD, MSc2, ; Kathy Robinson, PhD2; Kristin Delfino, PhD3; John Gao, MD, PhD4; Krishna Rao, MD, PhD5,*  \n1Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL, United States 2Department of Internal Medicine at Simmons Cancer Institute, Center for Clinical Research, Southern Illinois University School  \nof Medicine, Springfield, IL, United States  \n3Department of Surgery, Center for Clinical Research, Southern Illinois University School of Medicine, Springfield, IL,  \nUnited States  \n4Department of Laboratory Medicine, Springfield Memorial Hospital, Springfield, IL, United States 5Department of Internal Medicine at Simmons Cancer Institute, Southern Illinois University School of Medicine, Springfield, IL,  \nUnited States  \n*Corresponding author: Krishna Rao ([krao@siumed.edu](krao@siumed.edu)).  \nAbstract  \nIntroduction: ERBB2 is amplified or overexpressed in 15% to 20% of primary invasive breast cancers. Despite the aggressive nature of ERBB2-positive breast cancers, the development of anti-ERBB2 therapy has resulted in better prognoses. HScore is a scoring system that broadens immunohistochemistry (IHC) results into a quantitative range. The aim of this retrospective study was to evaluate whether the HScore can be used to predict all ERBB2 IHC-equivocal cases as positive or negative without the need for fluorescence in situ hybridization confirmation.  \nMethods: Image acquisition and processing tools were used on previously collected tissue slides from patients with ERBB2 IHC 2+ breast cancer from 2014 to 2023. After image acquisition, HScore values were calculated using variables from image analysis software.  \nResults: The mean HScore values in ERBB2-positive cases were higher (3.06) than in ERBB2-negative cases (2.62). Receiver operating characteristic curve analysis yielded an area under the curve of 0.668 (95% CI, 0.523-0.812), indicating poor predictive accuracy. The optimal HScore cutoff of 2.6007 provided moderate sensitivity (0.77) but limited specificity (0.58).  \nDiscussion: Although the HScore showed moderate predictive accuracy, it lacked the reliability to replace fluorescence in situ hybridization as the gold standard. Future research should focus on refining the methodology and integrating it with other diagnostic approaches to enhance accuracy and clinical utility.  \nKey words ERBB2, IHC, breast cancer  \nIntroduction  \nBreast cancer is the most common cancer in women and the second-leading cause of cancer-related deaths in women worldwide.1 Although breast cancer is commonly associated with women, it can also occur in men, with approximately 2800 cases diagnosed annually in the United States.2 Breast cancer–associated biomarker identification, including  \nestrogen receptor, progesterone receptor, and ERBB2, dramatically improved the ability to predict patient prognosis and tailor treatments. The ERBB2 protein is a receptor tyrosine kinase located on chromosome 17q21 that participatesin controlling how breast cells divide and repair themselves.3 ERBB2 gene amplification or ERBB2 protein overexpression, however, which is present in 15% to 20% of primary invasive breast cancers, can lead to breast cells to proliferate at an  \n© The Author(s) 2026. Published by Oxford University Press on behalf of American Society for Clinical Pathology.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is pro","cbCaikDRFuFF4Nt5","https://ap.wps.com/l/cbCaikDRFuFF4Nt5","pdf",1115242,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Discussion\n## Key words","[{\"question\":\"What is the purpose of using HScore in ERBB2 IHC-equivocal breast cancer?\",\"answer\":\"To determine whether HScore can predict ERBB2 IHC-equivocal (2+) cases as positive or negative, potentially avoiding FISH confirmation.\"},{\"question\":\"How were HScore values generated in the study?\",\"answer\":\"Image acquisition and processing were performed on previously collected tissue slides, and HScore values were calculated using variables from image analysis software.\"},{\"question\":\"What diagnostic performance did HScore show compared with FISH as the gold standard?\",\"answer\":\"HScore demonstrated moderate predictive accuracy (ROC AUC 0.668) but lacked reliability to replace FISH, which remains the reference method for ERBB2 status confirmation.\"}]","HScore as a diagnostic tool in ERBB2 equivocal (immunohistochemistry 2+) breast cancer | PDF",1790094055,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33a7f94e6c1d5ef90fd733b83f321364.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0934e4abfada86b6b3073bd8ab9cb8a8.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdf7493c8ceb63560e6cf7477b48861c.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eaef9c5e58c925b23b0198a4720a76cd.webp",980,1287]